Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Clinical use of the co-formulation of insulin degludec and insulin aspart

Research output: Contribution to journalReviewpeer-review


  1. Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus: A Systematic Review

    Research output: Contribution to journalLetterpeer-review

  2. Determinants of sexual function and dysfunction in men and women with stroke: A systematic review

    Research output: Contribution to journalReviewpeer-review

  1. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

    Research output: Contribution to journalJournal articleResearchpeer-review

  • A Kumar
  • T Awata
  • S C Bain
  • A Ceriello
  • G R Fulcher
  • A G Unnikrishnan
  • R Arechavaleta
  • G Gonzalez-Gálvez
  • T Hirose
  • P D Home
  • K Kaku
  • L Litwak
  • S Madsbad
  • M Pinget
  • R Mehta
  • A Mithal
  • M Tambascia
  • J Tibaldi
  • J S Christiansen
View graph of relations

AIMS: To provide a review of the available data and practical use of insulin degludec with insulin aspart (IDegAsp). Premixed insulins provide basal and prandial glucose control; however, they have an intermediate-acting prandial insulin component and do not provide as effective basal coverage as true long-acting insulins, owing to the physicochemical incompatibility of their individual components, coupled with the inflexibility of adjustment. The molecular structure of the co-formulation of IDegAsp, a novel insulin preparation, allows these two molecules to coexist without affecting their individual pharmacodynamic profiles.

METHODS: Clinical evidence in phase 2/3 trials of IDegAsp efficacy and safety in type 1 and type 2 diabetes mellitus (T1DM and T2DM) have been assessed and summarised.

RESULTS: In people with T2DM, once- and twice-daily dosing provides similar overall glycaemic control (HbA1c ) to current modern insulins, but with lower risk of nocturnal hypoglycaemia. In prior insulin users, glycaemic control was achieved with lower or equal insulin doses vs. other basal+meal-time or premix insulin regimens. In insulin-naïve patients with T2DM, IDegAsp can be started once or twice-daily, based on individual need. People switching from more than once-daily basal or premix insulin therapy can be converted unit-to-unit to once-daily IDegAsp, although this strategy should be assessed by the physician on an individual basis.

CONCLUSIONS: IDegAsp offers physicians and people with T2DM a simpler insulin regimen than other available basal-bolus or premix-based insulin regimens, with stable daytime basal coverage, a lower rate of hypoglycaemia and some flexibility in injection timing compared with premix insulins.

Original languageEnglish
JournalInternational Journal of Clinical Practice
Issue number8
Pages (from-to)657-67
Number of pages11
Publication statusPublished - Aug 2016

    Research areas

  • Journal Article, Review

ID: 48335670